The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.

Journal of Clinical Psychopharmacology
Marianne K KringenEspen Molden

Abstract

The antidepressant venlafaxine is largely O-desmethylated by CYP2D6, whereas CYP2C19 mediates an alternative metabolic route of venlafaxine through N-desmethylation. The aim of this study was to investigate the combined effect of genotype-predicted CYP2D6 and CYP2C19 phenotypes on serum concentrations of venlafaxine and metabolites in a large patient population. Patients were retrospectively included from a therapeutic drug monitoring service at Diakonhjemmet Hospital in Oslo (Norway) between January 01, 2007, and December 31, 2017. The study population was divided into different phenotype subgroups according to the combinations of CYP2D6/CYP2C19 phenotypes; intermediate metabolizers (IMs), poor metabolizers (PMs) and ultrarapid metabolizers, and compared using combined normal metabolizers (NMs) as reference. The dose-adjusted serum concentration of venlafaxine was 4- and 13-fold increased in combined CYP2D6 IM/CYP2C19 PMs and combined PMs, respectively, compared with combined NMs (P < 0.001). The sum concentration of venlafaxine + ODV (pharmacological active moiety) was increased 1.9 and 3.6-fold, respectively, in the same phenotype groups. Furthermore, the dose-adjusted active moiety exposure was similar in combined IMs as co...Continue Reading

References

Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S M FogelmanD J Greenblatt
Jan 14, 2000·Pharmacogenetics·E LessardJ Turgeon
May 13, 2006·The International Journal of Neuropsychopharmacology·Guy DebonnelPierre Blier
Sep 1, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Ellyn M JohnsonCharles F Reynolds
Sep 9, 2006·Journal of Clinical Pharmacy and Therapeutics·M E E ShamsS Härtter
Sep 7, 2007·Mayo Clinic Proceedings·Donald E McAlpineDavid A Mrazek
Mar 18, 2011·Clinical Pharmacology and Therapeutics·J J SwenH-J Guchelaar
Nov 15, 2011·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Marco VinettiPhilippe Hantson
Oct 17, 2013·Pharmacogenetics and Genomics·Katrin SangkuhlTeri E Klein
May 27, 2014·European Journal of Clinical Pharmacology·Ragnhild Birkeland WaadeEspen Molden
Sep 30, 2015·Therapeutic Drug Monitoring·Buster MannheimerEspen Molden
Apr 6, 2017·Clinical Pharmacology and Therapeutics·Y ZhouV M Lauschke
Nov 15, 2017·Clinical Pharmacology and Therapeutics·Andrea GaedigkUNKNOWN PharmVar Steering Committee
Jan 17, 2019·The International Journal of Neuropsychopharmacology·Ryosuke ArakawaJohan Lundberg

❮ Previous
Next ❯

Citations

Apr 28, 2021·Journal of Clinical Psychopharmacology·Kristine HoleTore Haslemo
Jul 23, 2021·Science Translational Medicine·Maaike van der LeeSeyed Yahya Anvar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.